van Rooij Willem Jan, Bechan Ratna S, Peluso Jo P, Sluzewski Menno
Department of Radiology, St Elisabeth Ziekenhuis; Tilburg, The Netherlands -
Department of Radiology, St Elisabeth Ziekenhuis; Tilburg, The Netherlands.
Interv Neuroradiol. 2014 Jul-Aug;20(4):428-35. doi: 10.15274/INR-2014-10047. Epub 2014 Aug 28.
Flow diverter devices became available in our department in 2009. We considered treatment with flow diverters only in patients with aneurysms not suitable for surgery or conventional endovascular techniques. This paper presents our preliminary experience with flow diverters in a consecutive series of 550 endovascular aneurysm treatments. Between January 2009 and July 2013, 550 endovascular treatments for intracranial aneurysms were performed. Of these, 490 were first-time aneurysm treatments in 464 patients and 61 were additional treatments of previously coiled aneurysms in 51 patients. Endovascular treatments consisted of selective coiling in 445 (80.8%), stent-assisted coiling in 68 (12.4%), balloon-assisted coiling in 13 (2.4%), parent vessel occlusion in 12 (2.2%) and flow diverter treatment in 12 (2.2%). Eleven patients with 12 aneurysms were treated with flow diverters. Two patients had ruptured dissecting aneurysms. One patient with a basilar trunk aneurysm died of acute in stent thrombosis and another patient died of brain stem ischaemia at 32 months follow-up. One patient had ischaemia with permanent neurological deficit. Two aneurysms are still open at up to 30 months follow-up. Flow diversion was used in 2% of all endovascular treatments. Both our own poor results and the high complication rates reported in the literature have converted our initial enthusiasm to apprehension and hesitancy. The safety and efficacy profile of flow diversion should discourage the use of these devices in aneurysms that can be treated with other techniques.
2009年,我们科室开始使用血流导向装置。我们仅考虑对不适合手术或传统血管内技术治疗的动脉瘤患者使用血流导向装置。本文介绍了我们在连续550例血管内动脉瘤治疗中使用血流导向装置的初步经验。2009年1月至2013年7月,共进行了550例颅内动脉瘤的血管内治疗。其中,490例为464例患者的首次动脉瘤治疗,61例为51例患者先前已栓塞动脉瘤的再次治疗。血管内治疗包括选择性栓塞445例(80.8%)、支架辅助栓塞68例(12.4%)、球囊辅助栓塞13例(2.4%)、载瘤动脉闭塞12例(2.2%)和血流导向治疗12例(2.2%)。11例患者的12个动脉瘤接受了血流导向治疗。2例患者为破裂性夹层动脉瘤。1例基底动脉主干动脉瘤患者死于支架内急性血栓形成,另1例患者在随访32个月时死于脑干缺血。1例患者出现缺血并伴有永久性神经功能缺损。2个动脉瘤在随访长达30个月时仍未完全闭塞。血流导向治疗占所有血管内治疗的2%。我们自己的不佳结果以及文献报道的高并发症发生率,已使我们最初的热情转变为担忧和犹豫。血流导向治疗的安全性和有效性情况应使人们不鼓励在可采用其他技术治疗的动脉瘤中使用这些装置。